CIK 0001439222 · Large accelerated filer
AGIOS PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- AGIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-649-8600
- Business address
- 88 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- AGIOS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $371,112
- in 2 filings, $371K under 10b5-1 plans
Net −$371,112. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −2,350 | 2,350 | ||
| 2025-02-05 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 | −2,272 | $34.39 | $78K | 5,437 |
| 2025-02-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 | +6,896 | 7,709 | ||
| 2025-02-01 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise · Restricted stock units 10b5-1 | −6,896 | 0 | ||
| 2025-01-06 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 | −2,804 | $32.18 | $90K | 18,906 |
| 2025-01-03 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 | +8,476 | 21,710 | ||
| 2025-01-03 | Milanova Tsveta Chief Commercial Officer | Option exercise · Restricted stock units 10b5-1 | −8,476 | 8,475 | ||
| 2024-12-11 | Scadden David Director | Option exercise 10b5-1 | +200 | $18.09 | $4K | 15,683 |
| 2024-12-11 | Scadden David Director | Sale 10b5-1 | −200 | $46.28 | $9K | 15,483 |
| 2024-12-11 | Scadden David Director | Option exercise · Stock options (right to buy) 10b5-1 | −200 | 29,107 | ||
| 2024-11-08 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | −772 | $56.09 | $43K | 813 |
| 2024-11-08 | Ballal Rahul D. Director | Option exercise 10b5-1 | +10,000 | $25.99 | $260K | 17,992 |
| 2024-11-08 | Ballal Rahul D. Director | Sale 10b5-1 | −3,571 | $57.24 | $204K | 14,421 |
| 2024-11-08 | Ballal Rahul D. Director | Sale 10b5-1 | −4,929 | $58.57 | $289K | 9,492 |
| 2024-11-08 | Ballal Rahul D. Director | Sale 10b5-1 | −1,500 | $59.21 | $89K | 7,992 |
| 2024-11-08 | Ballal Rahul D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 17,947 | ||
| 2024-11-07 | Ballal Rahul D. Director | Option exercise 10b5-1 | +10,000 | $25.99 | $260K | 17,992 |
| 2024-11-07 | Ballal Rahul D. Director | Sale 10b5-1 | −8,132 | $53.32 | $434K | 9,860 |
| 2024-11-07 | Ballal Rahul D. Director | Sale 10b5-1 | −1,868 | $54.41 | $102K | 7,992 |
| 2024-11-07 | Ballal Rahul D. Director | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 27,947 |
Page 18 of 48 · 941 trades